8.39
0.04 (0.48%)
| 前收盘价格 | 8.35 |
| 收盘价格 | 8.35 |
| 成交量 | 582,721 |
| 平均成交量 (3个月) | 849,453 |
| 市值 | 554,163,200 |
| 预期市盈率 (P/E Forward) | 80.65 |
| 价格/销量 (P/S) | 1.83 |
| 股市价格/股市净资产 (P/B) | 53.71 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2026 |
| 营业毛利率 | -20.40% |
| 营业利益率 (TTM) | -19.00% |
| 稀释每股收益 (EPS TTM) | -0.890 |
| 季度收入增长率 (YOY) | 15.50% |
| 总债务/股东权益 (D/E MRQ) | 2,353.84% |
| 流动比率 (MRQ) | 2.34 |
| 营业现金流 (OCF TTM) | -23.02 M |
| 杠杆自由现金流 (LFCF TTM) | -9.39 M |
| 资产报酬率 (ROA TTM) | -9.36% |
| 股东权益报酬率 (ROE TTM) | -949.45% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 看涨 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 看涨 | |
| 股票 | Evolus, Inc. Common Stock | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -3.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.67 |
|
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 5.46% |
| 机构持股比例 | 85.15% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合